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Abstract   
Transintestinal cholesterol excretion (TICE) is a major route for cholesterol elimination from the body and 
a potential therapeutic target for hypercholesterolemia. The underlying mechanism, however, is largely 
unclear and its contribution to cholesterol disposal from the body is obscured by the counteracting process 
of intestinal cholesterol reabsorption. To determine the quantity of TICE independent from its 
reabsorption, we studied two models of decreased intestinal cholesterol absorption. Cholesterol absorption 
was inhibited either by ezetimibe or, indirectly, by genetic inactivation of the intestinal apical sodium-
dependent bile acid transporter (ASBT, SLC10A2). Both ezetimibe treatment and Asbt inactivation 
virtually abrogated fractional cholesterol absorption (from 46% to 4% and 6%, respectively). In either 
model, fecal neutral sterol excretion and net intestinal cholesterol balance were considerably higher than 
in control mice (5- and 7-fold, respectively), suggesting that, under physiological conditions, TICE is 
largely reabsorbed. In both models, the net intestinal cholesterol balance was increased to a similar extent, 
but was not further increased when the models were combined, suggesting that the effect on cholesterol 
reabsorption was already maximal under either condition alone. Based on these findings, we hypothesize 
that inhibition of cholesterol (re)absorption combined with stimulation of TICE will be most effective in 
increasing cholesterol disposal.  
 
Keywords: ASBT inhibition, FXR, intestinal cholesterol absorption, transintestinal cholesterol excretion, 
ezetimibe  
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Introduction   
Atherosclerosis, leading to coronary artery disease and cerebrovascular accidents, accounts for around 
50% of deaths in Westernized countries and its prevalence is increasing in low- and middle-income 
countries (1, 2). The aetiology of atherosclerosis is complex and risk factors are both genetic and 
environmental. Hypercholesterolemia can contribute to the development of atherosclerosis via 
accumulation of cholesterol from low-density lipoproteins (LDL-c) in the arterial vessel wall (2, 3). 
Treatment options for hypercholesterolemia and atherosclerosis include lifestyle modifications (i.e. 
smoking cessation, increasing physical activity and improving diet quality (4, 5)), as well as drugs 
targeted at cholesterol metabolism. The most widely prescribed class of drugs are statins that inhibit 
hepatic cholesterol synthesis. Unfortunately, statins only reduce the cardiovascular disease risk by 15-37% 
(6). Novel proprotein convertase subtilsinkexin type 9 (PCSK9) inhibitors show promising results, but 
also limitations (7). Therefore, more effective or adjunct treatments are needed for the prevention and 
treatment of atherosclerosis.  
 
Cholesterol homeostasis in the body encompasses a highly regulated balance between cholesterol 
intake, de novo synthesis, and disposal, mainly via the feces as neutral sterols (NS; cholesterol and its 
metabolites produced by intestinal microbiota) or as bile acids (BAs). BAs are synthetized from 
cholesterol in the liver, secreted into the bile and predominantly stored in the gallbladder. Following a 
meal and gallbladder emptying, BAs are secreted via the bile into the duodenum, where they aid in the 
absorption of fat, cholesterol and fat-soluble vitamins. Under physiological conditions, about 95% of 
intestinal BAs are reabsorbed each cycle, mainly by ileal enterocytes via the apical sodium-dependent bile 
acid transporter (ASBT, SLC10A2), and transported back to the liver. This mechanism of enterohepatic 
circulation is tightly regulated by the BA-activated nuclear farnesoid X receptor (FXR) in both the liver 
and intestine (8).  
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Inducing fecal excretion of both NS and BAs has been used as a strategy to lower plasma cholesterol 
levels. Blocking cholesterol absorption by inhibiting the main intestinal cholesterol transporter, the 
Niemann-Pick C1-Like 1 (NPC1L1), increases fecal cholesterol excretion and hepatic LDL-receptor 
(LDLR) expression, and is used as adjunct therapy to statins to further reduce plasma LDL-c levels and 
improve cardiovascular outcomes (9). Increasing cholesterol excretion from the body can also be achieved 
by targeting BA homeostasis. BA sequestrants bind BAs inside the intestinal lumen, thereby preventing 
their reabsorption, ultimately resulting in increased fecal BA excretion and a compensatory increase in BA 
synthesis from cholesterol (10). BA sequestrants have been shown to effectively lower plasma LDL-c 
levels in animal models as well as humans (11). ASBT inhibition works via a similar mechanism and has 
also been shown to reduce hypercholesterolemia and atherosclerosis in several animal models (12–15). 
Inhibition of ASBT reduces reabsorption of BAs and, similar to BA sequestrants, this increases their fecal 
excretion which is compensated by increased hepatic synthesis from cholesterol. Interrupting the 
enterohepatic circulation by inhibiting ASBT decreases the BA pool (i.e. the total amount of BAs present 
in the enterohepatic circulation), because the induction of synthesis cannot completely compensate for the 
increased fecal loss (16). This results in a decreased availability of BAs in the intestinal lumen for the 
solubilisation of cholesterol, thereby lowering intestinal cholesterol absorption (17). Therefore, in contrast 
to ezetimibe which directly inhibits intestinal cholesterol absorption, ASBT inactivation indirectly lowers 
absorption of cholesterol through a reduction of the BA pool.   
 
Recently, a major non-biliary pathway that contributes to the fecal excretion of cholesterol has been 
identified. This pathway, known as transintestinal cholesterol excretion (TICE), is present both in mice 
and humans (18, 19). The molecular mechanism underlying TICE has not been fully elucidated. However, 
TICE is at least partly dependent on cholesterol transport by the ATP-binding cassette sub-family G 
members 5 and 8 (ABCG5/8) (20–22). Originally, Van der Velde et al. quantified TICE directly in 
intestinal perfusion studies (23, 24). TICE was also estimated in models with impaired biliary cholesterol 
secretion such as the Abcg8 or multidrug resistant protein 2, (Mdr2) knockout mouse (23).  This study and 
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others indirectly calculated TICE by subtracting dietary and biliary (or only dietary in the case of impaired 
biliary secretion) input from fecal neutral sterol (NS) output (reviewed in (25, 26)). In models of impaired 
biliary cholesterol secretion, such as the Mdr2 knockout mouse, fractional cholesterol absorption is still 
high with studies showing no reduction compared to wildtype controls (~50% absorption in both 
genotypes) (27)  to a reduction from 70% to 40% (28).  Therefore, the calculated TICE in these studies 
yields a minimum estimation as it is unclear to what degree reabsorption of transintestinally-excreted 
cholesterol contributed to fecal NS excretion. The notion that reabsorption of TICE occurs could be 
hypothesized based on experiments with ezetimibe, an NPC1L1 inhibitor, which increased fecal NS 
excretion beyond biliary and dietary input and potentiated the effects on calculated TICE by intestinal 
FXR activation (19, 22, 29, 30). While various  conditions, including high-fat diet feeding, liver X 
receptor (LXR) activation and (intestinal) FXR activation have been implied to affect TICE, the possible 
role of reabsorption of cholesterol originating from TICE has not been addressed rigorously (21–23).  
In the current study, we investigated the contribution of cholesterol (re)absorption of intestinally 
excreted cholesterol by using two models of impaired cholesterol (re)absorption. Firstly, we inhibited 
intestinal cholesterol (re)absorption by using ezetimibe, which inhibits NPC1L1. Secondly, we used Asbt
-/-
 
mice that display a partial impairment in cholesterol (re)absorption through reduction of the BA pool (17). 
In both models, we quantitated cholesterol fluxes and measured fractional cholesterol absorption. Lastly, 
we combined both models to determine the combined effect of ezetimibe and ASBT inhibition on 
cholesterol disposal from the body. 
  
 at University of G















 mice and wildtype (WT) littermates on a C57BL/6 were originally generated by P.A. Dawson 
(Emory University, Atlanta, GA) and bred at the UMCG animal facility. While there are established 
differences in sterol metabolism between male and female mice (31), most studies on intestinal cholesterol 
fluxes were performed on male mice on a C57BL/6 background (19–24, 29, 32). To be able to relate our 
results best to previously published studies only male mice (aged 10-18 weeks) were used. Mice were 
conventionally housed in individual cages in a temperature- and light-controlled facility with a 12-hour 
light-dark cycle. The mice had ad libitum access to water and maintenance laboratory chow 
(macronutrient ratio as % of total calories: fat: 7.5%, proteins: 17.5%, carbohydrates: 75%) containing 
0.008% cholesterol (RM1 FG, Special Diet Services, Witham Essex, England), with or without ezetimibe 
(0.005%, 50mg/kg chow) (Ezetrol, Pharmacy UMCG, Groningen, The Netherlands).   
Animal experiments were approved by the Ethics Committee for Animal Experiments of the University 
of Groningen. All experiments were performed in accordance with relevant guidelines and regulations 
(including laboratory and biosafety regulations). 
 
Cholesterol flux measurements 
Mice received the ezetimibe-enriched diet for 3 weeks. Cholesterol fluxes were measured in the last 10 
days by using a dual stable isotope tracer method as described (33). The experimental setup is shown in 
Figure 1. Three days prior to the start of the experiment, bloodspots and 24-hour feces were collected for 
baseline measurements and food intake and body weight were measured. On day 0, the mice were 
anaesthetized with isoflurane and given a retro-orbital injection of 0.3mg D5-cholesterol (Medical Isotopes 
Inc., Pelham, NH, USA) dissolved in 150μl Intralipid 20% (Fresenius Kabi, Den Bosch, The Netherlands) 
and an oral gavage of 0.6mg D7-cholesterol (Cambridge Isotope Laboratories, Inc, Andover, MA, USA) 
dissolved in 200μl medium chain triglyceride oil. Bloodspots were collected at the time points 3, 6, 12, 24, 
48, 72, 96, 120, 144 and 168 hours after labelled cholesterol administration. At the time point 168h (day 
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8), mice received water containing 2% of 1-
13C
acetate until termination, and bloodspots were collected 24, 
32, 48 and 72 hours after starting the 1-
13C
acetate. Body weight and food intake were determined and feces 
were collected daily from day 0 to day 10 (figure 1).  
On day 10, the mice were anesthetized by intraperitoneal injection of a mixture of Hypnorm 
(fentanyl/fluanisone; 1 ml/kg) and diazepam (10 mg/kg). The gallbladder was cannulated early in the light 
phase (at 9:00AM) as previously described (34). Bile collected in the first 5 minutes was discarded to 
avoid collection of concentrated bile. After this first 5 min, bile was collected for 20 minutes in pre-
weighed tubes with the mice placed in a humidified incubator (37ºC) to maintain body temperature. Blood 
was obtained via cardiac puncture. The small intestines were flushed with ice cold phosphate buffered 
saline (PBS) containing a protease inhibitor (cOmplete, Roche, Mannheim, Germany) and cut in three 
segments of equal length, the middle-piece from each segment was excised for gene analysis. All 
intestinal segments were immediately snap-frozen in liquid nitrogen.  
 
Bile acid and neutral sterol measurements 
Neutral sterols (cholesterol and its bacterial metabolites in fecal samples) were extracted from 50mg of 
air-dried, ground fecal samples as described by Ronda et al. (33). Briefly, feces was heated for two hours 
at 80ºC with a mixture of 1M sodium hydroxide and methanol (1:3). Neutral sterols were then extracted 2 
times with 2ml petroleum ether and derivatised with BSTFA-pyridine-TMCS (5:5:0.1). Bile acids were 
extracted from feces with Sep-Pak C-18 columns, methylated with methanol/acetyl chloride (20:1) and 
derivatised with BSTFA-pyridine-TMCS (5:5:0.1). Both neutral sterols and bile acids were measured by 
gas chromatography (GC) as previously described (35). The total amount of bile acids or neutral sterols 
was calculated as the sum of the individual species. 
For biliary bile acid measurements, bile samples were diluted 1000-fold with Milli-Q water. Samples 
were centrifuged at 15800 x g and the supernatant poured into a clean glass tube. The fluid was evaporated 
under nitrogen at 40°C. Before measuring, samples were reconstituted in 200 µL 50% methanol in water, 
vortexed for 60 s and centrifuged for 3 min at 1800 x g. The supernatant was transferred into a 0,2 µm 
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spin-filter and centrifuged at 2000 x g for 10 min. After filtering, the samples were transferred into vials 
and analyzed (10 µL injection volume). For the quantitative determination of bile acids we used a Nexera 
X2 Ultra High Performance Liquid Chromatography system (SHIMADZU, Kyoto, Japan), coupled to a 
SCIEX QTRAP 4500 MD triple quadrupole mass spectrometer (SCIEX, Framingham, MA, USA) 
(UHPLC-MS/MS). The LC-MS/MS system is controlled by Analyst MD 1.6.2  software. 
Biliary lipids were extracted from 15l of bile according to Bligh and Dyer (36) and, subsequently, 
biliary cholesterol was derivatised with BSTFA-pyridine-TMCS (5:5:0.1) for GC measurement (33). 
Fecal neutral sterol and bile acid excretion and dietary cholesterol intake were similar among all days. 
Data displayed in the figures and used to calculate the intestinal cholesterol balance, represent measured 
values for the last 24 hours (day 10). Net non-hepatobiliary cholesterol excretion was calculated as [fecal 
neutral sterol output - (dietary cholesterol intake + hepatobiliary secretion)]. Cholesterol synthesis and 
pool size were calculated as described in (33). 
 
Hepatic and plasma lipids  
Livers were mechanically ground in liquid nitrogen. Liver lipids were extracted from 15% 
homogenates in PBS according to Bligh and Dyer (36). Subsequently, liver total and free cholesterol and 
triglyceride levels were determined using commercially available reagents (DiaSys Diagnostic Systems, 
Holzheim, Germany and Roche Diagnostics, Mannheim, Germany). Plasma triglycerides, total cholesterol 
and free cholesterol were determined spectrophotometrically using the same kits. For plasma lipoprotein 
measurements, blood from individual mice was pooled for each experimental group. Plasma lipoproteins 
were fractionated using fast protein liquid chromatography (FPLC) on a Superose - 6 10/300 GL column 
(GE Healthcare, Uppsala, Sweden). Cholesterol and triglyceride concentrations of fractions were 
determined using commercially available reagents (DiaSys Diagnostic Systems and Roche Diagnostics). 
 
Gene expression analysis 
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Gene expression analysis was performed in liver and duodenum. Total RNA was isolated with TRI-
Reagent (Sigma, St. Louis, MO, USA) and quantified by NanoDrop (NanoDrop Technologies, 
Wilmington, DE, USA). cDNA synthesis was performed from 1μg of total RNA. Primers were designed 
with Primer-BLAST and optimized for use with SYBR Green Master Mix (Roche Diagnostics, 
Mannheim, Germany) (maximum product size 150 nucleotides). Real-time qPCR analysis was performed 
on a StepOnePlus™ Real-Time PCR System (Applied Biosystems, Thermo Fisher, Darmstadt, Germany). 




Unless otherwise stated, data are presented as Tukey plots where boxes represent the median with 
interquartile range (IQR) and whiskers extend to the largest value or 1.5 times the IQR if the largest value 
extends that. Statistical analyses were performed and graphs were created using GraphPad Prism 6 
(GraphPad Software, La Jolla, CA, USA). Differences between groups were assessed by 2-way ANOVA 
using Tukey’s post-hoc test. Significance is indicated as *P < 0.05,  **P < 0.01, ***P < 0.001. 
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Assessment of cholesterol (re)absorption in ezetimibe-treated mice  
We aimed to estimate the amount of cholesterol entering the intestine via TICE. To avoid interference 
of potential intestinal reabsorption, we first applied ezetimibe treatment and determined fractional 
cholesterol absorption using a dual stable isotope labelling approach (Fig. 2A). Ezetimibe prevents 
intestinal cholesterol absorption through inhibition of the internalization of the cholesterol transporter 
NPC1L1, which is required for intestinal cholesterol absorption in the small intestinal epithelium (37). 
Ezetimibe treatment virtually abrogated fractional cholesterol absorption (from 46% in untreated controls 
to 4% upon ezetimibe treatment, P < 0.001, Fig. 2A). In line with earlier studies (22), ezetimibe treatment 
increased fecal neutral sterol (NS) excretion 4-fold in WT mice (Fig.2B). Theoretically, there are three 
mechanisms possible for an increased fecal NS: 1) increased influx of cholesterol into the intestine (either 
via the bile, the diet or TICE), 2) decreased intestinal (re)absorption, or 3) a combination of these. Since 
cholesterol absorption is virtually abrogated by ezetimibe treatment, cholesterol (re)absorption can be 
considered minimal, leaving the three remaining fluxes as possibly causing the increased fecal NS: biliary 
secretion, dietary cholesterol intake and/or TICE (Fig. 3A). The resultant flux of excretion (i.e. TICE) 
minus (re)absorption was defined as net intestinal (cholesterol) balance. (Fig. 3A). Based on the difference 
between fecal NS excretion and the dietary and biliary cholesterol influx into the intestine, the net 
intestinal balance in ezetimibe-treated mice was estimated at 39 μmol/24h/100gBW (Fig. 3B-C). The 
estimated net intestinal cholesterol balance thereby largely exceeds the biliary and the dietary influx of 
cholesterol into the intestine. These data indicate that the profound increase in fecal NS is apparently for 
the largest part due to TICE, that is not reabsorbed upon ezetimibe treatment. 
 
Assessment of cholesterol (re)absorption in Asbt
-/-
 mice 
Theoretically, the results obtained in ezetimibe-treated mice could be specific for this mechanism of 
inhibition of cholesterol absorption and thereby not generalizable to other conditions of decreased 
cholesterol (re)absorption. We therefore performed similar experiments in another mouse model of 
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decreased cholesterol absorption and increased fecal NS excretion, the Asbt
-/-
 mice. The fractional 
cholesterol absorption in Asbt
-/-
 mice was strongly decreased, to a similar level of that of ezetimibe-treated 
WT mice (6% vs 4%, P = ns, Fig. 2A). In agreement with previous reports, Asbt
-/-
 mice had a 3-fold 
increased fecal NS excretion as compared to WT controls (P < 0.001, Fig. 2B)  (17). Under these 
conditions of virtually no cholesterol (re)absorption, the net intestinal cholesterol balance was 26 
μmol/24h/100gBW, slightly lower but in the same range as intestinal cholesterol balance in ezetimibe-
treated WT mice (P < 0.01, Fig. 3B-C). TICE was several fold larger than the biliary and dietary 
cholesterol influx into the intestine and, again, the increased fecal NS fraction could largely be attributed 
to non-reabsorbed cholesterol originating from TICE.  
We then investigated whether combining the two mechanisms of inhibiting (re)absorption would 
further affect these cholesterol fluxes across the intestine. Treatment of Asbt
-/-
 mice with ezetimibe, 
however, did not result in a significant (further) reduction of cholesterol absorption compared to untreated 
Asbt
-/-
 mice  (1% vs 6%, P = ns, Fig. 2A), nor did it affect either the fecal NS excretion in Asbt
-/-
 mice 
(Fig. 2B), the biliary or dietary cholesterol influx or the calculated net intestinal cholesterol balance (Fig. 
3B-C). This observation establishes impaired cholesterol (re)absorption as the mechanism underlying the 
increased fecal NS excretion in (untreated) Asbt
-/-
 mice.  
 
The mechanism of decreased cholesterol (re)absorption in Asbt
-/-
 mice 
For ezetimibe, the mechanism of inhibition of cholesterol (re)absorption has been directly related to 
inhibition of NPC1L1, the main protein responsible for cholesterol absorption (38). For Asbt
-/-
 
inactivation, however, the mechanism of decreased cholesterol (re)absorption has been less clear (39). 
Intestinal cholesterol absorption is strongly dependent on the intestinal availability of (hydrophobic) BAs 
(40). Decreased biliary BA secretion, due to increased intestinal BA loss and contraction of the BA pool, 
could underlie the decreased cholesterol (re)absorption. We therefore determined whether the interrupted 
enterohepatic circulation in Asbt
-/-
 mice quantitatively and/or qualitatively affected biliary BA secretion 
and fecal BA excretion. Fecal BA excretion was about 3-fold higher in Asbt
-/-
 mice compared to WT mice 
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(25 vs. 8 μmol/24h/100gBW,  P < 0.001, Fig. 4A). At the same time, mRNA level of cholesterol 7 alpha-
hydroxylase (Cyp7a1), the rate limiting enzyme in the conversion of cholesterol to BAs, was increased 7-
fold in Asbt
-/-
 mice as compared to WT mice (Fig. S1). Ezetimibe treatment did not change fecal BA 
excretion in WT mice, but slightly increased BA excretion in Asbt
-/-
 mice (33 vs 25 μmol/24h/100gBW,  P 
< 0.05, Fig. 4A). In line with interruption of the enterohepatic circulation of BAs and the subsequent 
contraction of the BA pool, the biliary secretion of BAs was strongly decreased in Asbt
-/-
 mice as 
compared to WT controls (-86%, P < 0.001, Fig. 4B). Ezetimibe did not significantly affect total biliary 
BA secretion in WT mice or Asbt
-/-
 mice (Fig. 4B). The composition of biliary BAs was more 
hydrophobic in Asbt
-/-
 mice compared to controls, as quantified by an increased Heuman hydrophobicity 
index (+0.2 vs -0.2, P < 0.001, Fig. 4C) (41). The increase in hydrophobicity could be attributed to a 
fractional increase of  taurodeoxycholic acid (TDCA)  (47% vs 4%, P < 0.001, Fig. 4D) and subsequent 
decrease in taurocholic acid (TCA) (35 vs 67%, P < 0.001, Fig. 4D) and tauro-β-muricholic acid 
(TβMCA) (2% vs 21%, P < 0.001, Fig 4D) in Asbt-/- mice compared to WT mice. Ezetimibe did not affect 
fecal BA composition (data not shown), biliary hydrophobicity (Fig 4C) or biliary BA profile (Fig 4D) in 
either WT or Asbt
-/-
 mice .  
Not only the absorption of cholesterol, but also that of dietary fatty acids was decreased in Asbt
-/-
 mice 
and this was slightly ameliorated by ezetimibe (Fig. 4E). Together, these findings indicate that the 
abrogated intestinal cholesterol absorption in Asbt
-/-
 mice primarily resulted from strongly reduced biliary 
BA secretion. Apparently, the decreased biliary BA secretion could not be compensated for by a more 
hydrophobic BA composition, despite the notion that hydrophobic BAs are more effective in aiding the 
micellar solubilization and subsequent absorption of cholesterol (40, 42).  
 
Intestinal and hepatic mRNA expression of genes involved in cholesterol homeostasis 
Theoretically, the decreased cholesterol absorption in Asbt
-/-
 mice could be due to downregulation of 
Npc1l1 expression in the duodenum, but the unaffected steady state mRNA levels did not support this 
possibility (Fig. 5A). A reduction in cholesterol absorption can affect intracellular cholesterol 
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concentrations, which is sensed by the liver X receptor (LXR). Therefore, we measured the expression of 
LXR target genes, the ATP-binding cassette (ABC) subfamily A member 1 (Abca1) and ABC subfamily 
G members 5 and 8 (Abcg5/8). Abcg5/8 promote cholesterol efflux from the cell and are known to be 
crucial for TICE (25, 43). Abca1 was decreased in WT ezetimibe-treated mice compared to WT controls 
and in Asbt
-/-
 mice compared to WT controls (Fig. 5A). Abcg5/8 showed a similar trend to Abca1, but the 
difference did not reach statistical significance (Fig. 5A).  
To assess the consequences of decreased intestinal cholesterol (re)absorption and increased BA 
synthesis  on hepatic cholesterol homeostasis, we also measured LXR target genes in the liver (Fig. 5B). 
Levels of mRNA of the low density lipoprotein receptor 1 (Ldlr1), of Abca1 and of the sterol regulatory 
element-binding protein-1c (Srebp1c) were not statistically different.  
 
Effects of ezetimibe treatment and Asbt inactivation on total sterol excretion and cholesterol synthesis  
Disposal of cholesterol from the body is achieved via excretion, either as NS or, after conversion, as 
BAs. We calculated the total sterol balance from total fecal sterol output and dietary sterol input without 
correction for de novo synthesis, which will be assessed later (schematically represented in Fig. 6). As this 
model includes all cholesterol fluxes into the intestinal lumen, it represents a total sterol input-output 
balance over the intestine. Dietary sterol input (composed of dietary cholesterol ingestion) was similar 
across the groups (Fig. 6A). Total fecal sterol output, calculated as the sum of NS and BA output, was 
elevated in Asbt
-/-
 control and WT ezetimibe-treated mice to a similar degree upon comparison to WT 
controls (Fig. 6B). In Asbt
-/-
 mice, ezetimibe treatment further augmented total sterol excretion in the form 
of BAs (by ~17%, P < 0.01, Fig. 6B). All mice displayed a negative intestinal sterol balance, implying 
that sterol output was greater than input (Fig. 6C). Total intestinal sterol balance in Asbt
-/-
 and ezetimibe-
treated WT mice was similarly negative (implying more disposal than input), although Asbt
-/-
 mice 
excreted more sterols in the form of BAs, whereas WT ezetimibe-treated mice excreted more in the form 
of NS. Ezetimibe treatment in Asbt
-/- 
mice caused a further decrease in the total sterol balance.  
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To maintain a steady state in the body, a negative intestinal sterol balance needs to be compensated for 
by increased cholesterol synthesis. Indeed, enhancing cholesterol disposal via inhibition of reabsorption 
induces a compensatory increase in de novo cholesterol synthesis (44). We determined cholesterol 
synthesis in the four experimental groups, using 
13
C-acetate labelled drinking water (33). Fig. 7A shows 
the fractional contribution of newly synthesized cholesterol in plasma. Cholesterol synthesis was increased 
to a similar extent in Asbt
-/-
 and ezetimibe-treated WT mice, compared to untreated WT mice. The changes 
in cholesterol synthesis rates coincided with a similar trend towards higher gene expression of HmG-CoA 
reductase (Hmgcr) in both Asbt
-/-
 groups and WT ezetimibe-treated mice (Fig. 7B). Ezetimibe treatment in 
Asbt
-/-
 mice further increased cholesterol synthesis compared to Asbt
-/-
 controls (Fig. 7A). The changes in 
cholesterol absorption and synthesis did neither affect plasma cholesterol levels, lipoprotein distribution or 
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We aimed to estimate to what extent cholesterol entering the intestinal lumen via TICE is reabsorbed, 
and thus does not contribute to fecal NS excretion. Our data demonstrate that, using two mechanistically 
different models of impaired cholesterol (re)absorption, the net intestinal cholesterol balance is similarly 
increased. This indicates that efficient reabsorption of TICE strongly limits the disposal of cholesterol 
from the body under physiological conditions. Therefore, to enhance cholesterol disposal from the body, 
strategies to stimulate TICE are expected to be most efficacious when they are combined with 
simultaneous inhibition of its reabsorption. 
 
Previous studies showed that ezetimibe increases fecal NS excretion beyond what is expected based 
upon the decrease in absorption of dietary and bile-derived cholesterol (18, 19, 22). Up to now, it had not 
been possible to distinguish conclusively whether the increase in fecal NS beyond dietary and biliary input 
was due to simulation of TICE or to decreased (re)absorption. In the present study, we used a simplified 
model based on a net intestinal cholesterol balance, calculated by subtracting dietary and biliary 
cholesterol input from fecal output (Fig. 2A). In this model, the net intestinal cholesterol balance could be 
induced via either stimulation of TICE, via reduced (re)absorption or via a combination of both. It should 
be noted that the net intestinal cholesterol balance encompasses the absorption of cholesterol originating 
from biliary and dietary origin and the loss of cholesterol in the form of shedding of intestinal cells (at 
least for the part that is not reabsorbed from the intestine). Based on the provided quantitative calculations 
and on the estimates in the literature (21, 23), these individual contributions, however, are much smaller 
than the excretion and reabsorption of transintestinally excreted cholesterol. Our data show that abrogating 
cholesterol absorption, either directly via ezetimibe or indirectly by reducing the BA pool through Asbt 
inactivation, elevated the net intestinal cholesterol balance to a similar extent. Under the conditions of 
impaired cholesterol (re)absorption, the net intestinal cholesterol balance is almost completely determined 
by TICE. Therefore, we argue that blocking intestinal cholesterol absorption results in increased fecal NS 
excretion primarily via inhibiting the reabsorption of a basal flux of transintestinally excreted cholesterol 
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into the intestine, which, under physiological conditions, would have been mostly reabsorbed. The 
reabsorption of transintestinally excreted cholesterol seems to be even more efficient than the 
(re)absorption of cholesterol from dietary or biliary origin. We cannot exclude that the excretion of 
cholesterol at the apical membrane of intestinal epithelial cells, i.e. close to the site of possible 
reabsorption, is responsible for this.  
 
The molecular mechanism underlying TICE is not fully understood. One explanation is based on the 
notion that there is spontaneous cholesterol transfer from lipoproteins to membranes in various tissues 
including the intestine (45). High intestinal bile phospholipid concentrations can potentially be involved in 
TICE due to their cholesterophilic properties (23, 46). Free cholesterol can transfer to phospholipid rich 
intestinal bile content and subsequently be excreted in the feces. It might be that under physiological 
conditions there is a basal flux of cholesterol from the blood to the membranes, the intestinal lumen and 
back. With either ezetimibe or Asbt deficiency, this basal cholesterol flux is interrupted at the level of 
reabsorption into the enterocyte. Based on this theory, the slight difference in intestinal cholesterol 
balance between WT mice treated with ezetimibe versus inactivation of Asbt (Fig. 2B), could be due to the 
higher biliary phospholipid secretion in the bile of WT ezetimibe treated mice compared to Asbt
-/-
 mice 
(Fig. S5).  
Lumenal BA concentrations, composition and subsequent FXR activation are altered in Asbt
-/- 
mice and 
might contribute to the observed TICE flux. The exact contribution of intestinal BAs to TICE, especially 
under physiological conditions, is unclear. BAs are essential for cholesterol absorption through formation 
of micelles to travel from the intestinal lumen across the unstirred water layer to the enterocyte. 
Cholesterol transport in the reverse direction (i.e. from enterocyte to lumen) also requires travelling across 
the unstirred water layer and could therefore also be (partly) dependent on BAs. However, this might very 
well occur with a different efficiency. In the original perfusion studies performed by van der Velde et al. 
hydrophobic bile acids (TCA, TDCA) were more efficient in increasing cholesterol in the perfusate (i.e. 
TICE) compared to hydrophilic species (UDCA) (23, 24). However, this effect was more dependent on 
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the presence of phospholipids than that of bile acids. Moreover, other factors in this artificial system, such 
as the absence of food or the rate of perfusion could have affected outcomes and cholesterol (or TICE) 
reabsorption. In the experiment, supraphysiological doses of BAs were used and no dose-response curve 
was established. It therefore remains unclear at what concentration BAs need to be present to cause this 
increase in TICE. Furthermore, the observations by Van der Velde et al. are in contrast to those by De 
Boer et al. who showed that using bile diverted rats that induction of TICE by intestinal FXR activation 
required a change of biliary bile acid composition towards a more hydrophilic profile (22). This is in line 
with another murine study using different FXR agonists and an earlier in vitro observation where UDCA 
was more efficient in promoting ABCG5/8 dependent cholesterol efflux than CA (47, 48). 
 
Another explanation for the slight difference in intestinal cholesterol balance could be the different 
mechanism underlying the reduction of cholesterol absorption in WT ezetimibe treated mice versus Asbt
-/-
 
mice. It is proposed that cholesterol either from the intestinal lumen or from endogenous sources first has 
to translocate into the brush border membrane (BBM) before it can be internalized together with NPC1L1 
into the enterocyte (30, 49). In Asbt
-/-
 mice the absorption defect is likely due to reduced micelle 
formation: the decreased intestinal availability of micellar BAs prevents luminal cholesterol from (re-
)entering the BBM and thereby its internalization by NPC1L1. Blocking NPC1L1 by ezetimibe is not 
expected to prevent cholesterol from entering the brush border membrane. Thus, there might be more 
cholesterol availability in the BBM upon ezetimibe treatment compared to inactivation of Asbt resulting in 
a higher efflux of cholesterol from the BBM to the lumen from both exo- and endogenous sources (partly 
mediated via Abcg5/8 (19, 30)). This hypothesis is supported by the fact that ezetimibe in Asbt
-/-
 mice did 
not significantly affect net intestinal cholesterol balance. In Asbt
-/-
 mice cholesterol from the intestine is 
not expected to reach the BBM and therefore blocking the internalization with NPC1L1 process has no 
relevant additional effect on intestinal and subsequent fecal cholesterol concentrations.  
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We showed that Asbt
-/-
 mice had a 3-fold increase in fecal BA and NS excretion. While it was 
previously reported that Asbt
-/-
 mice have decreased fractional cholesterol absorption (55% versus 74% in 
WT littermates) (12), it remained unclear whether this could quantitatively account for the strongly 
increased fecal NS excretion (17, 39). Our data show that fractional cholesterol absorption in Asbt
-/-
 mice 
was much lower (~6%), and even similar to that of WT mice treated with ezetimibe (~4%), suggesting 
that the increase in fecal NS excretion was mainly due to impaired cholesterol (re)absorption. The 
differences between the fractional absorption in our experiment and those by Dawson et al. could possibly 
be explained by differences in genetic background (C57BL6 in this experiment versus 129S6/SvEv by 
Dawson et al.), dietary composition (such as different cholesterol and fiber content) or methodology (dual 
tracer method with blood sampling in this experiment versus dual labeled isotope method with fecal 
sampling by Dawson et al.). Our conclusion that decreased absorption underlies the increase in fecal NS 
excretion in Asbt
-/-
 mice was further supported by the finding that treatment of Asbt
-/-
 mice with ezetimibe 
did not result in an additional increase in fecal NS excretion. Our interpretation of these two observations 
is that the increase in fecal NS excretion in Asbt
-/-
 mice is due to decreased intestinal cholesterol 
(re)absorption.  
 
Although we were able to profoundly increase fecal sterol output via inactivation of Asbt and/or 
ezetimibe treatment, plasma cholesterol levels and total body cholesterol pool did not change (Fig S2-S4). 
Additionally, bodyweight was similar in WT and Asbt
-/- 
mice and unaffected by ezetimibe treatment (data 
not shown). Maintaining cholesterol homeostasis is essential to the body as it is an important component 
of cells and precursor for steroid hormones. It has been shown that mice have a great capability to 
maintain the whole body cholesterol pool size under various conditions (50). However, modulating 
cholesterol fluxes can impact cholesterol distribution over the different compartments in the body, 
especially hepatic, plasma and lipoprotein levels. Ezetimibe has been shown in humans to effectively 
lower LDL-c while maintaining a constant cholesterol body pool size (51). Present observations together 
with the previously shown effects on hypercholesterolemia in humans and mice show the profound 
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capacity to modulate cholesterol fluxes and lipoprotein distribution without affecting homeostasis 
essential for sustaining development. Adaptation of the cholesterol de novo synthesis rate is a major 
mechanism to balance the body cholesterol pool size (Fig 7, Fig S4). It can therefore be predicted that 
simultaneous interference with the cholesterol synthesis capacity will allow more robust manipulations of 
cholesterol homeostasis, which could contribute to targeted therapeutic strategies. 
Challenging our current models by feeding a high plant sterol or high cholesterol diet potentially 
results in more pronounced changes in intestinal cholesterol fluxes. With higher lumenal cholesterol 
concentrations there could, for example, be a higher membrane cholesterol exchange rate resulting in a 
bigger difference of the intestinal cholesterol balance between ezetimibe and Asbt inhibition (30). While 
these experiments are interesting and relevant for the clinical implications of cholesterol absorption 
inhibiting therapies, it is beyond the scope of our current study where we specifically aimed at 
demarcating the role of reabsorption of TICE under physiological conditions.  
 
Ezetimibe did not affect fecal neutral sterol excretion in Asbt
-/- 
mice but did augment fecal BA 
excretion resulting in increased total fecal sterol excretion. Asbt
-/- 
mice have a profoundly induced Cyp7a1 
expression (Fig. S1), a compensatory reaction to account for fecal BA loss. Therefore, the further 
augmented cholesterol synthesis by ezetimibe in Asbt
-/- 
mice compared to untreated Asbt
-/- 
mice (Fig. 6A) 
might be preferentially converted to BAs in the presence of high Cyp7a1 expression. An elevation in 
hepatic BA synthesis upon ezetimibe treatment in Asbt
-/- 
mice is supported by an increase in fecal BA 
excretion, which was absent upon ezetimibe treatment in WT mice. Previous studies on the effect of 
ezetimibe on fecal BA excretion have been conflicting, varying from no change in mice and an increase in 
humans (19) to no effect in either mice and humans (51). Both ezetimibe and ASBT inhibition have 
similar benefits on atherosclerosis development in mouse models (52). However, combining both 
therapies to combat atherosclerosis has to our knowledge not been investigated. While ezetimibe is not 
able to augment NS excretion further in addition to ASBT inhibition, a combination of these two 
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therapeutic strategies might still be beneficial due to the added increase in cholesterol and subsequent BA 
synthesis.   
 
Altogether, our results demonstrate that most TICE is counteracted by (re)absorption. Based on these 
findings we propose a model of net intestinal cholesterol balance that represents the resultant flux of 
intestinal excretion (or TICE) and (re)absorption and is calculated as [fecal neutral sterol excretion] - 
[dietary + biliary cholesterol input] (Fig. 2A).  While previous studies have estimated TICE via this 
calculation, they lacked the concept that TICE is also subjected to reabsorption. Additionally, we showed 
that inactivation of Asbt can be used as another model to potently inhibit intestinal cholesterol absorption. 
Combining inhibition of intestinal cholesterol (re)absorption with active induction of TICE is expected to 
further enhance the disposal of cholesterol from the body and is therefore an interesting target for the 
prevention and treatment of hypercholesterolemia, with or without additional manipulation of de novo 
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Fig. 1. Experimental schedule, adapted from (21). 
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Fig. 2. Intestinal cholesterol absorption and fecal neutral sterol excretion in WT and Asbt
-/-
 mice 
with and without ezetimibe treatment. Fractional cholesterol absorption (A) measured by stable dual 
isotope method. Total neutral sterol excretion in feces (B); n=5-6 per group. 
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Fig. 3. Proposed model for intestinal cholesterol fluxes and calculated net intestinal cholesterol 
balance for WT and Asbt
-/-
 mice with and without ezetimibe treatment. Net intestinal (cholesterol) 
balance represents [intestinal excretion (i.e. TICE)]-[intestinal (re)absorption] (A), calculated net intestinal 
cholesterol balance (B) and resultant cholesterol fluxes according to the proposed model (C). Values in 
μmol/24h/100gBW; n=5-6 per group. 
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Fig. 4. Changes in fecal and biliary bile acids and intestinal fat absorption upon ezetimibe treatment 
and Asbt deletion in mice. Total fecal bile acid excretion (A), total biliary bile acids secretion (B), biliary 
hydrophobicity index based on Heuman values (C), biliary bile acid composition (D) and intestinal fatty 
acid absorption (E); n=5-6 per group. 
 
 
 at University of G












Fig. 5. Expression of genes related to cholesterol homeostasis in WT and Asbt
-/-
 mice with and 
without ezetimibe treatment. Duodenal expression of genes related to cellular cholesterol homeostasis 
(A) and hepatic expression of LXR target genes (B),  mean ± SEM; n=5-6 per group. 
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Fig. 6. Schematic representation of the total sterol balance over the intestine, calculated via dietary 
cholesterol intake and total sterol output of WT and Asbt
-/-
 mice with and without ezetimibe 
treatment. Dietary cholesterol intake (A), total fecal sterol excretion (B) and net total sterol balance over 
the intestine (C); n=5-6 per group. 
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Fig. 7. Changes in cholesterol synthesis upon ezetimibe treatment and Asbt
-/-
 in mice. Fractional 
contribution of newly synthesized cholesterol in plasma. Hepatic (A) and duodenal (B) Hmgcr gene 
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